The Characterization and Discovery of Novel Autoantigens and Epitopes in Type 1 Diabetes (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8T).
March 26, 2018 and November 6, 2018
April 26, 2018 and December 6, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
No late applications are allowed for this Funding Opportunity Announcement.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.